Selective Targeting of M3 Muscarinic Receptors: an Opportunity for Improved Treatment of Upper Gastrointestinal Carcinomas
Pharmacy & Pharmacology International Journal · 2014
DOI: 10.15406/ppij.2014.01.00001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy & Pharmacology International Journal, 2014. Verfasst von Vikas Sehdev. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Upper Gastrointestinal (GI) Carcinomas are one of the most morbid forms of cancers that are inherently resistant to chemotherapeutic regimens. The G-protein coupled receptors (GPCRs) are the largest family of cell surface receptors that have recently emerged as significant modulators of cancer cell growth, survival, and metastasis. Owing to the normal physiologic role of muscarinic receptors, a major sub-class of GPCRs, many epithelial cells undergoes proliferation when exposed to acetylcholine. Since majority of the cancers are epithelial in origin, cancer cells frequently take over the philological machinery associated with muscarinic receptors and undergo uncontrolled proliferation, avoid cell death, and exhibit invasion and migration. The M3 sub-type of muscarinic receptors is over expressed in tumors of different types. In this review we focus on the oncogenic signaling mechanisms activated by the M3 receptors. The manuscript highlights the importance of M3 receptor as a potent therapeutic target for selective treatment of Upper GI Carcinomas. We also reported, for the very first time, that M3 receptor mRNA is significantly over expressed in Upper GI Carcinoma tissue samples. In addition, we also showed that M3 -specific anti-muscarinic agents have considerable anticancer activity in Upper GI Cancer cells. This review serves as foundation for future studies delineating the anti-tumor effect of M3 -specific anti-muscarinic agents as single agents or in combination in Upper GI Carcinoma.
Zitieren
APA
Sehdev, V. (2014). Selective Targeting of M3 Muscarinic Receptors: an Opportunity for Improved Treatment of Upper Gastrointestinal Carcinomas. Pharmacy & Pharmacology International Journal. https://doi.org/10.15406/ppij.2014.01.00001
Vancouver
Sehdev V. Selective Targeting of M3 Muscarinic Receptors: an Opportunity for Improved Treatment of Upper Gastrointestinal Carcinomas. Pharmacy & Pharmacology International Journal. 2014. doi:10.15406/ppij.2014.01.00001
BibTeX
@article{Sehdev2014,
author = {Sehdev, Vikas},
title = {Selective Targeting of M3 Muscarinic Receptors: an Opportunity for Improved Treatment of Upper Gastrointestinal Carcinomas},
journal = {Pharmacy & Pharmacology International Journal},
year = {2014},
doi = {10.15406/ppij.2014.01.00001}
}
EUVIMED